"The treatment of XDR-TB has been disastrous since the discovery of this form of the disease," said Jay Achar, an infectious disease specialist and medical advisor on TB at MSF. "Having access to effective treatment regimens will give people hope for treatment and help programs limit transmission of this deadly bacteria." Although simpler and safer treatment regimens remain necessary, the short duration of this new regimen is an important step in the right direction. "

Pretomanid was developed by TB Alliance, a non-profit organization, funded by governments (Australia, Germany, United Kingdom, and United States) and philanthropic sources, in the hope that this organization will continue to grow. will stick to its stated mission: "dedicated to the discovery, development and distribution of better, more effective and affordable TB drugs available to those in need".

In addition, TB Alliance should be awarded a priority check for tropical diseases (PRV) *, which it can sell for a substantial amount.

MSF is calling on TB Alliance to use this financial reward to make sure the drug is registered and made available at an affordable price, quickly.

"This newly approved pretomanid treatment regimen could save the lives of people with XDR-TB, but it's not time to celebrate," said Sharonann Lynch, Policy Advisor on HIV and TB. for the MSF access campaign. "The approval of this new scheme by the US FDA is only the first step. We now need pretomanid to be registered and available at an affordable price in all countries, giving priority to those who are most affected by TB. "

In April of this year, TB Alliance granted the first license to the US pharmaceutical company Mylan for the manufacture, registration and supply of pretannid.

To date, TB Alliance and Mylan have not released the pretenderid award. It has been estimated that generic versions of pretomanid could be produced and sold at a profit ranging from $ 0.36 to $ 1.14 per day.

The lowest overall prices for the other two drugs in the regimen, bedaquiline and linezolid, are already around $ 3 per day; people in need of this treatment will have to take it for six months, for a total price of US $ 548, before taking into account the pretender's additional price.